Mosaic ImmunoEngineering, Inc. (OTCMKTS:CPMV) Short Interest Down 66.7% in January

Mosaic ImmunoEngineering, Inc. (OTCMKTS:CPMV) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 200 shares, a decline of 66.7% from the December 31st total of 600 shares. Based on an average daily trading volume, of 800 shares, the short-interest ratio is presently 0.3 days.

Mosaic ImmunoEngineering Stock Performance

OTCMKTS CPMV remained flat at $0.98 on Tuesday. The company’s stock had a trading volume of 25 shares, compared to its average volume of 564. The business has a 50 day moving average price of $0.88 and a 200-day moving average price of $0.88. Mosaic ImmunoEngineering has a 12-month low of $0.10 and a 12-month high of $1.13. The company has a market cap of $7.10 million, a PE ratio of -6.53 and a beta of 0.27.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.